FDA approves Mallinckrodt’s regenerative skin burn graft after 4-month delay
Following months of regulatory delays in the wake of the COVID-19 pandemic, the FDA has finally approved Mallinckrodt’s regenerative tissue graft for the treatment of deep partial-thickness burns, also referred to as second-degree burns.